We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+85.72%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$73.2M
Cap. Flow
-$340M
Cap. Flow %
-27.05%
Top 10 Hldgs %
36.58%
Holding
220
New
69
Increased
26
Reduced
46
Closed
56

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.6M
2
GOSS icon
Gossamer Bio
GOSS
+$8.85M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.61M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.3M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$6.53M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$23.1M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
3
IMVT icon
Immunovant
IMVT
+$12M
4
ARGX icon
argenx
ARGX
+$11.4M
5
VSTM icon
Verastem
VSTM
+$7.36M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$777B
$216M 17.18%
700,000
-250,000
-26% -$73.2M
BPMC
2
PUT
DELISTED
Blueprint Medicines
BPMC
$31.2M 2.48%
400,000
+334,000
+506% +$22.6M
QQQ icon
3
CALL
Invesco QQQ Trust
QQQ
$455B
$30.9M 2.46%
+125,000
New +$28M
CCXI
4
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$28.8M 2.29%
+500,000
New +$27.2M
ARGX icon
5
PUT
argenx
ARGX
$57.4B
$28.3M 2.25%
125,800
– –
XBI icon
6
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$28M 2.23%
250,000
– –
RETA
7
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$26.1M 2.07%
+167,100
New +$25.4M
ZYME icon
8
CALL
Zymeworks
ZYME
$1.68B
$25.2M 2.01%
+700,000
New +$25.8M
FXI icon
9
PUT
iShares China Large-Cap ETF
FXI
$4.31B
$23.8M 1.9%
+600,000
New +$23.4M
ASND icon
10
CALL
Ascendis Pharma A/S
ASND
$16.7B
$21.4M 1.71%
+145,000
New +$19.9M
CLDX icon
11
Celldex Therapeutics
CLDX
$2.74B
$21.4M 1.7%
+1,647,439
New +$7.3M
VNQ icon
12
PUT
Vanguard Real Estate ETF
VNQ
$39.9B
$19.6M 1.56%
+250,000
New +$19M
MRNA icon
13
PUT
Moderna
MRNA
$21.6B
$19.3M 1.53%
+300,000
New +$16.4M
ACC
14
PUT
DELISTED
American Campus Communities, Inc.
ACC
$19.2M 1.53%
+550,000
New +$18.2M
XLRN
15
CALL
DELISTED
Acceleron Pharma
XLRN
$17.9M 1.42%
187,700
-22,500
-11% -$2.17M
MYOK
16
PUT
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$17.4M 1.39%
180,600
-239,000
-57% -$19.9M
OCUL icon
17
Ocular Therapeutix
OCUL
$1.86B
$17.1M 1.36%
2,055,977
+497,041
+32% +$3.29M
MRTX
18
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$17.1M 1.36%
150,000
+1,100
+0.7% +$107K
BPMC
19
DELISTED
Blueprint Medicines
BPMC
$15.7M 1.25%
+201,662
New +$13.6M
INCY icon
20
CALL
Incyte
INCY
$23.5B
$15.6M 1.24%
+150,000
New +$14.5M
TARA icon
21
Protara Therapeutics
TARA
$229M
$15.5M 1.23%
527,964
+77,192
+17% +$2.39M
OHI icon
22
PUT
Omega Healthcare
OHI
$15.4B
$14.9M 1.18%
+500,000
New +$14.8M
GBT
23
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.5M 1.16%
230,000
+140,000
+156% +$9.6M
BTAI icon
24
BioXcel Therapeutics
BTAI
$26.5M
$14.3M 1.13%
16,801
-26,556
-61% -$17.3M
XLF icon
25
PUT
State Street Financial Select Sector SPDR ETF
XLF
$55.5B
$13.9M 1.1%
+600,000
New +$13.6M
1
2 3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Ikarian Capital held 220 positions worth $1.26B, down 5.5% from $1.33B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital withdrew a net $340M in Q2 2020, closing 56 positions and reducing 46 holdings. Its most notable exit was Acceleron Pharma, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 20% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Blueprint Medicines worth $15.7M.

  • Ikarian Capital's largest Q2 2020 buy was Blueprint Medicines: 201,662 shares worth $15.7M.
  • Ikarian Capital added most to bluebird bio in Q2 2020, an estimated $5.73M increase.
  • Ikarian Capital's biggest Q2 2020 reduction was BioXcel Therapeutics, cutting an estimated $17.3M.
  • Ikarian Capital fully exited Acceleron Pharma in Q2 2020, selling an estimated $23.1M.
  • Ikarian Capital's ten largest holdings make up 37% of its $1.26B portfolio in Q2 2020.
  • Ikarian Capital opened 69 new positions and closed 56 in Q2 2020.
  • Ikarian Capital's portfolio value fell 5.5% quarter-over-quarter to $1.26B.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.